JP2008526724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526724A5 JP2008526724A5 JP2007548904A JP2007548904A JP2008526724A5 JP 2008526724 A5 JP2008526724 A5 JP 2008526724A5 JP 2007548904 A JP2007548904 A JP 2007548904A JP 2007548904 A JP2007548904 A JP 2007548904A JP 2008526724 A5 JP2008526724 A5 JP 2008526724A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- cycloalkyl
- substituted
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 49
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 22
- 239000011780 sodium chloride Substances 0.000 claims 22
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 125000002877 alkyl aryl group Chemical group 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 4
- 201000002674 obstructive nephropathy Diseases 0.000 claims 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- 125000005842 heteroatoms Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- JBXUWTJKJKKFAZ-UHFFFAOYSA-N 4-[3-(piperidin-4-ylmethyl)phenyl]pyridine Chemical compound C=1C=CC(C=2C=CN=CC=2)=CC=1CC1CCNCC1 JBXUWTJKJKKFAZ-UHFFFAOYSA-N 0.000 claims 1
- 102100000071 ADGRF5 Human genes 0.000 claims 1
- 101710005044 ADGRF5 Proteins 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- -1 or optionally OR 6 Chemical group 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- UDPYUAHSZFGRJO-UHFFFAOYSA-N tert-butyl 4-[(3-pyridin-4-ylphenyl)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CC1=CC=CC(C=2C=CN=CC=2)=C1 UDPYUAHSZFGRJO-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0428514.4 | 2004-12-31 | ||
| GBGB0428514.4A GB0428514D0 (en) | 2004-12-31 | 2004-12-31 | Compounds |
| PCT/GB2005/050266 WO2006070208A1 (en) | 2004-12-31 | 2005-12-30 | Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526724A JP2008526724A (ja) | 2008-07-24 |
| JP2008526724A5 true JP2008526724A5 (US07846941-20101207-C00217.png) | 2008-12-04 |
| JP4916452B2 JP4916452B2 (ja) | 2012-04-11 |
Family
ID=34179041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548904A Expired - Fee Related JP4916452B2 (ja) | 2004-12-31 | 2005-12-30 | Ｇｐｃｒ作動薬としてのピリジン、ピリミジン、およびピラジンの誘導体 |
Country Status (9)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8293751B2 (en) | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| EP2308840A1 (en) * | 2005-06-30 | 2011-04-13 | Prosidion Limited | GPCR agonists |
| MX2008003634A (es) * | 2005-09-16 | 2009-10-08 | Arena Pharm Inc | Moduladores del metabolismo y tratamiento de los trastornos metabolicos. |
| EP2369341A3 (en) | 2006-04-11 | 2012-01-04 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| AU2007334519A1 (en) | 2006-12-14 | 2008-06-26 | Merck Sharp & Dohme Corp. | Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
| EA015129B1 (ru) | 2007-01-04 | 2011-06-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
| EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| US20100286112A1 (en) | 2007-09-10 | 2010-11-11 | Oscar Barba | Compounds for the treatment of metabolic disorders |
| CA2697551C (en) | 2007-09-20 | 2013-03-12 | Irm Llc | Piperidine derivatives as modulators of gpr119 activity |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| WO2009106565A1 (en) * | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Agonists of gpr119 |
| WO2009106561A1 (en) * | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| CN102083794A (zh) * | 2008-05-05 | 2011-06-01 | 安姆根有限公司 | 作为γ分泌酶调节剂的脲化合物 |
| US8742117B2 (en) | 2008-12-24 | 2014-06-03 | Cadila Healthcare Limited | Oxime derivatives |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| KR20120046188A (ko) | 2009-06-24 | 2012-05-09 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 신규 화합물, 약제학적 조성물 및 이에 관련된 방법 |
| WO2010149685A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
| BR112013008100A2 (pt) | 2010-09-22 | 2016-08-09 | Arena Pharm Inc | "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles." |
| SG188547A1 (en) | 2010-10-08 | 2013-04-30 | Cadila Healthcare Ltd | Novel gpr 119 agonists |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| EP2643311A1 (en) | 2010-11-26 | 2013-10-02 | Lupin Limited | Bicyclic gpr119 modulators |
| WO2012118850A1 (en) | 2011-02-28 | 2012-09-07 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| CN103958502B (zh) | 2011-08-04 | 2016-02-10 | 阵列生物制药公司 | 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物 |
| PL3321262T3 (pl) | 2012-03-01 | 2021-06-28 | Array Biopharma, Inc. | Inhibitory kinaz serynowo/treoninowych |
| EP2877464B1 (en) * | 2012-07-24 | 2016-08-24 | Boehringer Ingelheim International GmbH | N-cyclopropyl-n-piperidinyl-amide derivatives and their use as gpr119 modulators |
| WO2014036015A1 (en) | 2012-08-27 | 2014-03-06 | Array Biopharma Inc. | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
| CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
| MX2017016530A (es) | 2015-06-22 | 2018-03-12 | Arena Pharm Inc | Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1). |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629325A (en) * | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| WO1998040356A1 (fr) * | 1997-03-12 | 1998-09-17 | Banyu Pharmaceutical Co., Ltd. | Medicaments contenant des derives d'aminopyridine comme ingredient actif |
| GB0014022D0 (en) * | 2000-06-08 | 2000-08-02 | Novartis Ag | Organic compounds |
| US20030022891A1 (en) * | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
| AU2002255597B8 (en) * | 2001-02-28 | 2006-10-26 | Merck Sharp & Dohme Corp. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| EP1383501B1 (en) | 2001-02-28 | 2007-04-04 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| WO2003027096A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors |
| TWI330183B (US07846941-20101207-C00217.png) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| GB0203778D0 (en) | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
| SE0203654D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
| US8293751B2 (en) * | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| WO2005003101A2 (en) * | 2003-07-02 | 2005-01-13 | Biofocus Discovery Limited | Pyrazine and pyridine derivatives as rho kinase inhibitors |
| US8207147B2 (en) * | 2003-12-24 | 2012-06-26 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
-
2004
- 2004-12-31 GB GBGB0428514.4A patent/GB0428514D0/en not_active Ceased
-
2005
- 2005-12-30 AT AT05821785T patent/ATE479677T1/de not_active IP Right Cessation
- 2005-12-30 ES ES05821785T patent/ES2350729T3/es active Active
- 2005-12-30 WO PCT/GB2005/050266 patent/WO2006070208A1/en active Application Filing
- 2005-12-30 JP JP2007548904A patent/JP4916452B2/ja not_active Expired - Fee Related
- 2005-12-30 US US11/794,641 patent/US8173807B2/en not_active Expired - Fee Related
- 2005-12-30 DE DE602005023343T patent/DE602005023343D1/de active Active
- 2005-12-30 SI SI200531147T patent/SI1838698T1/sl unknown
- 2005-12-30 EP EP05821785A patent/EP1838698B1/en active Active
